11:30 AM
May 11, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >